TDC
TXMD icon

Thompson Davis & Co’s TherapeuticsMD TXMD Stock Holding History

Thompson Davis & Co’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10
Closed -$3K – 1214
2016
Q3 		$3K Hold
10
– – 0.01% 948
2016
Q2 		$4K Hold
10
– – 0.01% 843
2016
Q1 		$3K Sell
10
-10
-50% -$3.41K ﹤0.01% 899
2015
Q4 		$10K Buy
20
+10
+100% +$3.69K 0.01% 662
2015
Q3 		$3K Hold
10
– – ﹤0.01% 967
2015
Q2 		$4K Buy
+10
New +$3.53K ﹤0.01% 964

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Davis & Co's TXMD Position: Q4 2016 in Review

Thompson Davis & Co sold out of TherapeuticsMD (TXMD) in Q4 2016, closing a stake of 10 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in TXMD in Q2 2015 and held it in 6 quarters. The position peaked at $10K in Q4 2015. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

  • Thompson Davis & Co reported no remaining TherapeuticsMD position as of Q4 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 10 TherapeuticsMD shares in Q4 2016, an estimated $3K.
  • Thompson Davis & Co first reported a position in TherapeuticsMD in Q2 2015 and held it in 6 quarters.
  • Thompson Davis & Co's TherapeuticsMD position peaked at $10K in Q4 2015.
  • 146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.